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Cardiovascular disease (CVD) remains the major cause of death
in patients with end-stage renal disease (ESRD). Traditional risk
factors do not explain the high prevalence of CVD in this
population, and other non-traditional cardiovascular (CV) risk
markers have now been described. Therefore, the potential
relationship between CVD and phenotypic and genotypic risk
markers was investigated prospectively in incident dialysis
patients cohort. The 279 patients (244 on hemodialysis,
35 on peritoneal dialysis) within the Diamant Alpin Dialysis
Cohort Study were investigated. Phenotypic and genotypic
parameters were determined at dialysis initiation, patients
monitored over a 2-year period, and CV events (morbidity and
mortality) recorded. Globally, 82 CV events occurred and 26
patients (9.3%) died from CVD, whereas 28 (10%) died from
non-CV causes. Previous CV events were strongly predictive of
CV events occurrence, whatever patients had had one (hazard
ratio (HR) 2, 95% confidence intervals (CI) 1.1–3.5) or more
(HR 3.9, 95% CI 2.1–7.1) CV accidents before starting dialysis.
Both lipoprotein(a) (HR 1.67, 95% CI 1–2.5) and total plasma
homocysteine at cutoff 30 lmol/l (HR 1.7, 95% CI 1.1–2.8)
were independent predictors of CV events outcome. In the
subgroup of patients with homocysteine o30 lmol/l,
methylenetetrahydrofolate reductase (MTHFR) TT was the sole
biological parameter predictive of CV event outcome (HR 2.5,
95% CI 1.1–10, P¼ 0.03). ESRD patients who enter chronic
dialysis with a previous CV event, high total homocysteinemia
levels, or MTHFR 677TT genotype must be considered at high
risk of incident CV events.
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Cardiovascular disease (CVD), that is, myocardial infarc-
tion, cerebrovascular or lower extremity peripheral arterial
occlusive disease remains the major cause of death in
patients with end-stage renal disease (ESRD). The risk for
developing such a cardiovascular (CV) event is 5–30 times
higher than in the general population.1,2 Moreover, infra-
clinical manifestations of atheroma, such as arterial stiffen-
ing, vascular calcifications, or left ventricular hypertrophy,
are clearly more frequent and severe in patients on renal
replacement therapy than in an age-matched general
population.3,4 Whereas most of these factors already play
a deleterious role at less advanced stages of chronic kidney
disease, others are more specific of the dialysis phase.
Traditional CV risk factors and/or markers such as smoking,
hypertension, diabetes mellitus, hypoalbuminemia, dys-
lipidemia, and/or secondary hyperparathyroidism do not
explain per se the high prevalence of vascular disease in this
population and are relatively limited predictors of CVD
mortality and morbidity in ESRD patients.4
Several recent reports have suggested a role for the
other so-called non-traditional biological risk markers in
the pathogenesis of CVD, such as elevated total homo-
cysteinemia levels (tHcy),5 lipoprotein(a) (Lp(a)),6 auto-
antibodies against oxidized low-density lipoprotein,7 as well
as genetic factors such as allele epsilon E4 of apolipo-
protein E,8 genetically determined size polymorphism of
apolipoprotein A,9 the C677T polymorphism of the 5,
10-methylenetetrahydrofolate reductase (MTHFR) gene,10
the DD polymorphism of the angiotensin-converting enzyme
gene,11 and the homozygous 4G/4G polymorphism of the
plasminogen activator inhibitor-1 gene.12 However, the link
between these different biological parameters and the CV
risk had not been demonstrated so far in a prospective
study.
Therefore, we have undertaken a prospective 2-year
observational study, aiming to investigate in multivariable
models the potential relationship between the CV mortality–
morbidity and the clinical and more recently described
biological (both phenotypic and genotypic) risk markers in a
cohort of incident ESRD patients.
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DESCRIPTION OF THE STUDY COHORT
Protocol
The Diamant Alpin Collaborative Dialysis study was
conducted in eight dialysis centers of a homogeneous Alpin
region covering several millions inhabitants in three adja-
cent countries of Rhoˆne-Alpes (France), Piemonte and Valle
d’Aosta (Italy), and Lausanne (Switzerland). The study
protocol was approved by the concerned national, regional,
and institutional ethical committees.
Out of 296 patients initiating chronic dialysis during a
17-month-period in the eight participating centers, 279
accepted and signed the informed consent form and were
enrolled before their fourth dialysis session. Among those
279 patients, 263 also accepted the separate genetic analysis
consent form. The clinical characteristics of the patients who
refused study enrolment or its genetic part were no different
from those who participated in the study. Baseline clinical
variables and routine biological parameters were collected
at dialysis start. The demographic, clinical, biological, and
genetic aspects of the cohort at the dialysis start were recently
published.13,14
At dialysis initiation, 117 (42%) of these patients had
already experienced a CV event. They exhibited specially
increased tHcy and Lp(a) levels, although the distribution of
Lp(a) phenotype, MTHFR 677TT, angiotensin-converting
enzyme DD, and plasminogen activator inhibitor-1 4G/4G
was similar to that of the reference population. Finally, none
of the analyzed phenotypical and genotypical parameters was
associated with the existence of a previous CV event.13
Follow-up
Among the cohort (n¼ 279), 244 patients were treated by
hemodialysis and 35 (12.5%) by peritoneal dialysis. Perito-
neal dialysis was most often performed under its continuous
ambulatory form. The median number of hemodialysis
sessions was three per week (95% confidence intervals (CI)
1–5) and the duration of the hemodialysis sessions was 3 h
and 30 min (95% CI 2 h–7 h and 30 min). The dialysers used
were synthetic high flux in 33%, synthetic low flux in 30%,
and cellulose-modified low-flux filter in 37%.
Patients’ data were monitored every 4 months during the 2
years of follow-up. Data were recorded on a specific common
observation sheet and stored in a centralized database on an
anonymous basis. Among the 279 patients, 28 (10%) died
from causes other than CV disease (see Results), 16 (5.7%)
benefited from renal transplantation, 11 (3.9%) were
transferred or lost to follow-up, and three (1.1%) patients
retracted their consent during the study. Hypertensive and
dyslipidemic patients were defined as patients taking anti-
hypertensive or lipid-lowering drugs, respectively, at the
entry of the study. CV events were defined as documented
myocardial infarction, de novo angina pectoris or coronary
revascularization, ischemic stroke, or peripheral arterial
occlusive disease needing surgical and/or radiological treat-
ment. Cardiac death was defined as death caused by cardiac
arrhythmia, myocardial infarction, or heart failure.
RESULTS
Patients population and outcome
The mean age (7SD) of the 279 patients was 63.7713.7
years, ranging from 22 to 92 years, and the gender ratio
(male/female) 1.73; 252 (90.3%) of the patients were hyper-
tensive and received a single (20.8%) or double or more
(67.7%) antihypertensive treatment. In addition, 84 (30%)
had type II diabetes mellitus, 81 (29%) received a lipid-
lowering drug, and 49 (17.6%) were current smokers.
Before the start of dialysis, 117 (42%) patients had
already experienced an adverse CV event: 72 (61.5%) had had
one vascular localization and 45 (38.5%) more than 1. These
events were peripheral artery disease in 26% of the cohort,
ischemic cerebro-vascular disease in 16%, and coronary
artery disease in 22% (among which 12% myocardial
infarction). Details have been published elsewhere.13
During the 2-year follow-up period, 82 patients (29.4%)
experienced a CV event (Figure 1): 26 peripheral arterial
occlusive disease (31.7%), 10 ischemic stroke (12.2%), and 46
coronary events (56.1%). Moreover, among the patients with
coronary events, two simultaneously experienced peripheral
arterial occlusive disease and two ischemic stoke. The risk
of CV event was not related to the chosen dialysis
method (hemo- vs peritoneal dialysis, P¼ 0.27) nor the type
of hemodialysis filter.
A total of 54 patients died during this observational
period: 26 (9.3%) from CV events and 28 (10.0%) from non-
CV deaths owing to various causes (neoplasia, 11; infectious
problems, five; acute hemorrhagic bleeding, four; cachexia,
three; dialysis withdrawal, three; necrotic enteritis, one; and
pulmonary embolism, one).
Prediction analysis of CV mortality–morbidity
(1) Among the classical clinical variables, only age, male
gender, dyslipidemia, and previous CV events were
predictive of CV outcome in a univariate model
(Table 1).
(2) Among the studied biological variables (n¼ 261
patients, i.e. 93.5% of the cohort), the following
parameters were statistically significant (Table 1):
K Lp(a) (4300 mg/l) level was one of the pheno-
typical parameters associated with CV outcome
(hazard ratio (HR) 1.61, 95% CI 1.01–2.56). Lp(a)
levels were not correlated to creatininemia (r¼ 0.07;
P¼ 0.25). Moreover, tHcy levels did not influence
Lp(a) levels (r¼ 0.06; P¼ 0.36).
K tHcy: out of 279 patients, 245 (93.8%) had a tHcy
414 mmol/l, unrelated to folic acid or vitamin B12
deficiency,13 nor to plasma creatinine (r¼ 0.12,
P¼ 0.39). In this population, plasma tHcy failed
to independently predict CV event at the cutoff of
the reference value (14 mmol/l) (HR 1.24, 95% CI
0.54–2.86, P¼ 0.6). As the mean plasma tHcy level
observed in this cohort was about 30 mmol/l, we
tested the prediction power of homocysteine at this
cutoff. In our population, 157 (60.1%) patients had
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tHcy o30 mmol/l and 104 (39.8%) X30 mmol/l. As
a result, tHcy 430 mmol/l was predictor of adverse
CV outcomes (HR 1.73, 95% CI 1.11–2.71) (Figure 2
and Table 1).
(3) Genotypical analysis: The deleterious role of a high
tHcy was reinforced by the MTHFR 677TT genotype
(n¼ 260), which was the sole informative genotypical
parameter (HR 2.44, 95% CI 1.44–4.15) in this study
(Table 1). This genotype was recorded in 32 (12.3%)
patients of the cohort. Among these 32 patients, 14
(43.8%) had a tHcy level o30 mmol/l. For the 82 CV
events, 78 patients (38 with tHcy o30 mmol/l and 40
with tHcy X30 mmol/l) had a genotypic analysis;
among them, 18 (23%) were homozygous MTHFR
TT. This represents a frequency twice that in the whole
cohort. Moreover, the MTHFR TT genotype was more
frequent in the CV event population with low tHcy:
among the patients with tHcy 430 mmol/l, 14 (9%)
were MTHFR TT, compared to eight MTHFR TT
patients among the 38 CV event patients (21%) with
tHcy o30 mmol/l (Figure 3).
(4) MTHFR 677TT patients were characterized by a higher
value of tHcy (33.7, 31.2, and 27.8 mmol/l for MTHFR
TT, CT, and CC, respectively, P¼ 0.07). However, no
interaction was established between MTHFR genotype
and tHcy levels on CV risk (P¼ 0.12). A great number
of MTHFR 677TT patients were deficient in folic acid,
6.5 versus 1.3% for non-TT, P¼ 0.05. In patients with
tHcy levels 430 mmol/l, CVD occurred preferentially
during the second year of the observational study. In
contrast, the incidence of CV events was similar during
the first and second year of the follow-up for the
MTHFR 677TT population. For non-CV deaths, tHcy
and MTHFR were not significant predictive parameters
(P¼ 0.43 and 0.7, respectively).
(5) None of the other tested parameters (autoantibodies
against anti-oxidized low-density lipoprotein, Apo(a)
and haptoglobin phenotype, angiotensin-converting
enzyme DD, ApoE, and plasminogen activator inhibi-
tor-1 4G) were predictive for the occurrence of CV
events (Table 1).
(6) In a multivariate analysis (n¼ 260 assessable patients),
previous CV events were still strongly predictive for
adverse CV events outcome in patients presenting
with 1 (HR 2.0, 95% CI 1.1–3.5) or more (OR 3.9,
95% CI 2.1–7.1) CV accidents (Table 2). In contrast,
advanced age, dyslipidemia, and gender were no more
predictive.
Both Lp(a) (HR 1.67, 95% CI 1.04–2.63) and tHcy
X30 mmol/l (HR 1.7, 95% CI 1.1–2.8) were independent
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Figure 1 | Actuarial CV event-free survival curves for fatal and
non-fatal CV events during the 2-year follow-up (n¼ 279). Each
point denotes a CV event.
Table 1 | Predictive univariate model for CV morbidity and
mortality
HR 95% CI P
Gender (male)* 1.69 1.05–2.78 0.03
Age 470 years* 2 1.3–3.22 0.001
Smokers 1.41 0.82–2.44 0.22
Dyslipidemia* 1.59 1.02–2.5 0.04
Diabetes mellitus 1.45 0.92–2.27 0.1
Hyperparathyroidism 1.15 0.72–1.85 0.54
Albuminemia o30 g/l 1.04 0.59–1.83 0.89
CRP 410 mg/l 1.33 0.85–2.05 0.2
Previous CV events*
n=1 2.45 1.45–4.17 0.0009
n 41 5.24 3.06–8.96 o0.0001
Lp(a) 4300 mg/l* 1.61 1.01–2.56 0.04
ApoA isoforms 1.32 0.8–2 0.25
Anti-oxidized LDL antibodies
(for each 100 AU increase)
0.99 0.96–1.04 0.5
Homocysteine X30 mmol/l* 1.73 1.11–2.71 0.016
ApoE (E4 allele) 0.74 0.39–1.41 0.36
MTHFR TT* 2.44 1.44–4.15 0.0009
ACE DD 0.87 0.56–1.41 0.57
PAI1 4G4G 1.61 0.53–3.12 0.16
Haptoglobin 2.2 1.18 0.75–1.82 0.47
Classical clinical and biological risk markers (n=279 patients) and specific
phenotypical and genotypical studied parameters (n=261, except for MTHFR
analysis, n=260) are presented. Data are expressed as hazard ratio (HR) and 95%
confidence interval (CI).
*Indicates a statistically significant parameter.
Abbreviations: ACE, angiotensin-converting enzyme; ApoA, apolipoprotein A; ApoE,
apolipoprotein E; CRP, C-reactive protein; CV, cardiovascular; LDL, low-density
lipoprotein; Lp(a), lipoprotein(a); MTHFR, methylenetetrahydrofolate reductase;
PAI-1, plasminogen activator inhibitor-1.
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Figure 2 | Actuarial CV event-free survival curves for fatal and
non-fatal CV events during the two-year follow-up. Patients were
divided into two groups according to total plasma homocysteine
levels, X30 or o30mmol/l. Data were adjusted for other indepen-
dent predictors of CV events. Each point denotes a CV event.
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predictors of CV events outcome. Interestingly, MTHFR
677TT failed to predict such events in the entire studied
population (OR 1.43, 95% CI 0.83–2.5) (Table 2). However,
as the MTHFR genotype determines tHcy levels, it would not
be surprising that genotype TT, which increases tHcy levels,
failed to be informative in the group with high tHcy levels
during multivariate analysis. Therefore, we tested the
prediction power of the MTHFR 677TT genotype in the
subgroup of patients with tHcy values o30 mmol/l. In this
population (n¼ 151), MTHFR 677TT was the sole variable
(HR 2.5, 95% CI 1.1–10, P¼ 0.03) (Figure 3a) together with
previous CV events, which were predictive of CV event. As
expected, the MTHFR genotype was not predictive in the
subgroup (n¼ 99) with high tHcy levels (HR 1.0, 95% CI
0.47–2.5, P¼ 0.9) (Figure 3b).
Discussion
Despite technical improvements in dialysis therapy, patients
with ESRD still have a significantly decreased life expec-
tancy.15 This difference is mainly owing to CVD, which
remains as their predominant cause of death.1,2,15,16
Among our Diamant Alpin prospective cohort, 117 (42%)
ESRD patients had already experienced an adverse CV event
before the dialysis, confirming that atherosclerotic CVD is
often present already at the initiation of dialysis therapy.17–19
In addition, a total of 82 out of our 279 cohort patients
(29.4%) experienced a CV event during the 2-year follow-up,
causing the death of 26 patients. These numbers emphasize
the high frequency of CVD in ESRD patients before as well as
after the initiation of dialysis therapy.
Conventional CV risk factors (i.e. Framingham risk
factors) cannot completely explain this high prevalence.20
On the contrary, in dialysis patients, low levels of blood pres-
sure and serum cholesterol could even be better predictors of
CV mortality than high values; this observation has led to the
challenging ‘reverse epidemiology’ concept.21 In addition, the
uremic syndrome, in particular secondary hyperparathyroid-
ism – and eventually some aspects of its treatment – may
aggravate vascular calcifications before as well as after the
dialysis initiation.22 Finally, chronic inflammation owing to
superimposed infection or to the dialysis therapy in itself has
been implicated in the malnutrition–inflammation–athero-
sclerosis syndrome.23
Over the last years, other non-traditional genotypic and
phenotypic risk markers were described.5–12 However, the
impact of these parameters on CV events and outcome
remains questioned, as most often demonstrated in non-
prospective studies. Therefore, the present investigation was
undertaken in an incident cohort of patients who had to
initiate dialysis therapy.
Among the traditional predictors of CV adverse events,
those identified in our study were male gender, age 470 years,
dyslipidemia, and previous CVD (Table 1). After adjusting for
confounding variables by multivariate model, only previous
CV events had a powerful influence, increasing the risk for
incident cardiac complications by about four times (Table 1).
Studying death during the first year of dialysis, Joki et al.24
previously showed that the severity of coronary atherosclerosis
predicts death in the first year of hemodialysis. Moreover, the
high prevalence of both CV risk markers and CVD was also
reported in predialysis chronic renal failure17,18,24 and in
patients with less severe kidney dysfunction.18,25,26 Our
prospective data on CV morbidity completely agree with
these results and also emphasize the need for early and
optimal medical intervention to reduce the development and/
or deterioration of CVD before dialysis has to be initiated.
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Figure 3 | Actuarial CV event-free survival curves for fatal and
non-fatal CV events during the 2-year follow-up. Patients were
divided into two groups according to MTHFR genotype, TT
homozygous and CC homozygous or CT heterozygous. Data were
depicted for homocysteine levels o30mmol/l (n¼ 151, (a)) or for
homocysteine levels X30mmol/l (n¼ 99, (b)). Data were adjusted
for other independent predictors of CV events. Each point denotes
a CV event.
Table 2 | Predictive multivariate model for CV morbidity and
mortality (n=260)
HR 95% CI P
Gender (male) 1.41 0.85–2.38 0.18
Age 470 years 1.43 0.91–2.5 0.15
Dyslipidemia 1.43 0.91–2.5 0.13
Previous CV events*
n=1 2 1.1–3.5 0.015
n41 3.9 2.1–7.1 o0.0001
CRP 1.41 0.88–2.27 0.15
Lp(a) 4300 mg/l* 1.67 1.04–2.63 0.035
Homocysteine 430mmol/l* 1.7 1.1–2.8 0.027
MTHFR TT 1.43 0.83–2.5 0.17
Data are expressed as hazard ratio (HR) and 95% confidence interval (CI).
*Indicates a statistically significant parameter.
Abbreviations: CRP, C-reactive protein; CV, cardiovascular; Lp(a), lipoprotein(a);
MTHFR, methylenetetrahydrofolate reductase.
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Within the non-traditional CV risk predictors, multiple
biological parameters related to renal dysfunction have been
described without knowing exactly whether they are just
markers of the CV risk or if these and/or other factors
interact to increase the risk of adverse outcomes.
Lp(a) is a highly atherogenic particle, and its plasma
concentrations are markedly elevated in patients with renal
disease. The plasma concentrations of this lipoprotein are
an independent risk marker for atherosclerosis.27 Besides,
Lp(a) level was previously demonstrated to be associated with
prevalent CV disease in a cross-sectional study.28 We show
here prospectively that Lp(a) levels appear to be helpful to
identify dialysis patients at high risk of incident CVD.
Hyperhomocysteinemia has been described as an inde-
pendent risk factor for CVD in the general population.29 As
patients with renal impairment have plasma levels of tHcy
that are 2–8 times those of the general population,13,30,31
these high levels may constitute per se a risk marker for CVD
in ESRD.32 Hyperhomocysteinemia was recently shown to
predict CV events in patients on at least 6 months of regular
dialysis treatment.33 In our study, we showed that hyper-
homocysteinemia was an independent predictor of CV
outcome already at the entry on dialysis, increasing the
risk by 1.7 (95% CI 1.1–2.8) for the 2 subsequent years. How-
ever, such an information was valid only for tHcy levels
X30 mmol/l. This was also the case in the report of Bostom,32
who observed an increased CV risk in dialysis patients when
tHcy was X27 mmol/l. Similar results were also reported by
Mallamaci et al.33 describing in an incident study an elevated
risk for the third tertile of homocysteine levels.
As patients with tHcy levels 430 mmol/l developed CVD
preferentially during the second year of our prospective
study, – whereas the incidence of CV events was similar
during the first and second year of follow-up for the MTHFR
677TT population – , it would be tempting to consider
hyperhomocysteinemia as marker of a chronic effect on
arterial disease and not of a fast vascular aggressor system.
High homocysteine plasma levels appear to be related to
failure in enzymes implicated in the folate-homocysteine
pathway, among which is the 5,10-MTHFR.34 The homo-
zygous C677T polymorphism, which is responsible for a
strong decrease of MTHFR activity, was proven to be
associated with a higher risk of both CVD in ESRD35,36 and
arterio-venous fistula obstruction.37 However, the predictive
value of the 677TT genotype as a CVD incidence marker in
ESRD patients remained to be confirmed in prospective
studies. In our study, the C677T mutation was informative of
CV outcome (Table 1). More interestingly, the prediction
power of this genotypic characteristic was strictly related to the
tHcy level. Indeed, MTHFR 677TT patients were characterized
by higher values of tHcy.13 So, for patients with tHcy levels
X30mmol/l, the knowledge of the MTHFR genotype was
without interest (HR 1, 95% CI 0.47–2.5, P¼ 0.9) (Figure 3b).
Conversely, for lower levels of tHcy, – which were not
predictive of CV events – , the 677TT genotype was the sole
biologically tested parameter identified as an independent risk
factor (HR 2.5, 95% CI 1.1–10, P¼ 0.03) for developing CVD
(Figure 3a). This result might be of importance to define
optimal CV therapeutic prevention. Group B vitamins
regulate the homocysteine metabolism and the efficacy of B
vitamins administration on plasma tHcy level was described to
depend on MTHFR genotype.38 Although a great number of
our patients with TT genotype were deficient in folic acid, we
did not find a clear association between the vitamin status and
level of this amino acid. This suggests that the sole substitution
with vitamin B could not be sufficient to correct tHcy levels in
an ESRD population. Moreover, mild hyperhomocysteinemia
was described to be refractory to physiological doses of folic
acid. In our report, tHcyo30mmol/l was found in 20 patients
(56.2%) with TT genotype, who must still be considered at
high CV risk on the basis of the genotype. In these particular
patients, the sole correction of plasma tHcy level might be
difficult to obtain and probably insufficient to control CVD.
In conclusion, previous CV events and parameters of
homocysteine metabolism, together with Lp(a), were pre-
dictive of CV adverse event occurrence in ESRD patients
entering dialysis. This observation stresses the importance of
establishing therapeutic preventive strategies to modify the
CV risk. Interventional trials to validate the most effective
medical interventions for stopping the progression of CVD in
these patients should be undertaken.
MATERIALS AND METHODS
Laboratory measurements
Both whole blood and plasma samples were stored at 201C in each
center and then centralized at the biological reference site for specific
determinations. For technical reasons (sample transport and so on),
specific biological analyses were possible in 261 patients and
MTHFR analysis in 260 patients. Therefore, multivariate analysis
was tested only on the 260 patients for whom complete data were
available for this analysis.
The biological methods used in this study are described
elsewhere.13 Briefly, Lp(a) (normal rangeo300 mg/l) was measured
by an immunoturbidimetric method; tHcy (normal ranges 4–14
mmol/l) was determined using a highly sensitive capillary gas
chromatography method.39 Haptoglobin phenotype was determined
by agarose gel electrophoresis followed by tetramethylbenzidine
staining, using purified haptoglobin phenotype standards.
After DNA extraction, genotyping was realized by specific PCR
amplification and enzymatic digestion, followed by electrophoresis
on 1% agarose gel.
The other routine biological measurements were performed at
each individual center.
Statistical analysis
Descriptive statistics are reported as frequency and percentage for
categorical data, or as mean and two SDs for continuous data. CV
outcomes were studied by actuarial method. Univariate analysis was
carried out by the log rank test and expressed as HR with 95% CI.
The major clinical and baseline biological variables (n¼ 279) and all
specific biological variables (n¼ 261, except MTHFR n¼ 260) were
tested in the univariate analysis. Multivariate analysis was tested on
the 260 patients for whom complete data were available, using Cox
model and expressed as adjusted HR with 95% CI. Only significant
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variables from the univariate analysis were tested in the multi-
variate models. For all tests, statistical significance was defined as
Po0.05.
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